Okuyama et al. demonstrated that ILC2 and CD8+ T cell in tumors of IL-33-treated mice express OX40L and OX40, respectively, and blockade of the OX40L–OX40 pathway suppressed the anti-tumor effects of IL-33 in the tumor microenvironment in vivo [62]. The gene discussed is TNFRSF4; the disease is neoplasm.